Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008295 | 0.84 | L3MBTL1 (0.62) | L3MBTL1TDP1FFAR1TBXAS1KDM4E | |
| SCHEMBL6498671 | 0.76 | L3MBTL1 (0.52) | L3MBTL1TDP1FFAR1TBXAS1KDM4E | |
| SCHEMBL28644740 | 0.73 | RAB9A (0.71) | L3MBTL1TDP1HTTNPC1POLB | |
| SCHEMBL16614410 | 0.72 | L3MBTL1 (0.65) | L3MBTL1TDP1HTTNPC1POLB | |
| SCHEMBL1009895 | 0.72 | L3MBTL1 (0.65) | L3MBTL1TDP1HTTNPC1POLB | |
| SCHEMBL6551488 | 0.72 | L3MBTL1 (0.65) | L3MBTL1TDP1HTTNPC1POLB | |
| SCHEMBL11196123 | 0.72 | SMN1; SMN2 (0.51) | L3MBTL1TDP1FFAR1KDM4EHTT | |
| SCHEMBL27089915 | 0.72 | L3MBTL1 (0.65) | L3MBTL1TDP1HTTNPC1POLB | |
| SCHEMBL1005774 | 0.71 | L3MBTL1 (0.45) | L3MBTL1TDP1TBXAS1ALDH1A1 | |
| SCHEMBL16614396 | 0.71 | L3MBTL1 (0.67) | L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861432-B2 | Piperazine derivatives that destabilize androgen receptors | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20040009969-A1 | Piperazine derivatives that destabilize androgen receptors | SCHERING AG (DE) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009969-A1 | Piperazine derivatives that destabilize androgen receptors | AR, FSHR, GNRHR | L3MBTL1 4567/4885TDP1 4281/4885FFAR1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.